Results 81 to 90 of about 274,722 (228)

Navigating Oral Food Challenges in Clinical Trials to Keep the Science Moving Forward

Allergy, EarlyView.
ABSTRACT The oral food challenge (OFC) has long been the reference standard for food allergy diagnosis, as well as to confirm natural development of oral tolerance. The utilization of OFCs has significantly broadened from its role in defining disease to defining participant eligibility, individual allergen reactivity thresholds and treatment outcomes ...
Edwin H. Kim, J. Andrew Bird, Helen A. Brough, David M. Fleischer, Stacie M. Jones, Ildiko Kun, Wayne Shreffler, Claire Van Eenwyk, Brian P. Vickery, Julie Wang, Alexandra F. Santos   +10 more
wiley   +1 more source

Immunotherapy for food allergy: current proposals to improve safety and efficacy

Pediatric Respirology and Critical Care Medicine
This review mainly focuses on the novel approaches that improve the safety and efficacy of immunotherapies, namely SLIT [alone or as pre-treatment of oral immunotherapy (OIT)], epicutaneous immunotherapy (EPIT), combination of anti-IgE into OIT or ...
Wing Tung Crystal Wan
doaj   +1 more source

Update on clinical research for food allergy treatment

Frontiers in Allergy, 2023
The incidence of IgE-mediated food allergy (FA) has continued to increase over the years which places substantial burden on patient health and quality of life. With no cure for this disease, the mainstay of management has been allergen avoidance. However,
Joshua Fowler, Jay Lieberman
doaj   +1 more source

Patient‐Derived IgG Epitope Mapping of Bet v 1 Reveals Hypoallergenic Peptide Candidates for Safe and Next‐Generation Allergen Immunotherapy

Clinical &Experimental Allergy, EarlyView.
Mapping IgG epitopes of the major birch allergen Bet v 1 identified patient‐derived, hypoallergenic peptides that did not trigger degranulation. These findings support a novel, safer approach for peptide‐based allergen immunotherapy that leverages naturally induced IgG specificities from allergic individuals. ABSTRACT Background Allergen immunotherapy (
Lara Šošić, Marta Paolucci, Alessandro Streuli, David A. Melillo, Tianchi Jiang, Raffaela Campana, Claudia C. V. Lang, Thomas M. Kündig, Christian Steuer, Klaus Eyer, Pål Johansen   +10 more
wiley   +1 more source

Epicutaneous immunotherapy: the next step for food allergy desensitization [PDF]

Expert Review of Clinical Immunology, 2018
Food allergy is a global health problem affecting 5-8% of adults and children respectively [1]. The current standard of care for food allergy remains strict avoidance of the allergen, reading produ...
openaire   +2 more sources

Randomised, Double‐Blinded, Placebo‐Controlled Challenge Test With Single Food Items in Dogs With Atopic Dermatitis and Adverse Food Reactions

Veterinary Dermatology, Volume 37, Issue 2, Page 247-256, April 2026.
ABSTRACT Background Identification of offending foods in dogs with adverse food reactions is usually based on “deterioration” during open food challenges. Objectives To examine the placebo effect during double‐blinded, placebo‐controlled food challenges using a predefined set of criteria for relapse.
Evi I. Sofou, Elisa Samuel, Svetlina Aleksandrova, Manolis Chatzis, Manolis N. Saridomichelakis   +4 more
wiley   +1 more source

Immunotherapy for Food Allergy: Myth or Reality?

Jurnal Penyakit Dalam Indonesia, 2019
Allergic reaction to food can have serious consequences. The only treatment option is strict allergen avoidance, but accidental ingestions happen frequently and can lead to severe and potentially life-threatening allergic reactions.
Gatot Soegiarto
doaj   +1 more source

Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy

Expert Review of Clinical Immunology
Introduction DBV712 250 µg (also referred to as Viaskin Peanut or peanut patch; Viaskin is a trademark of DBV Technologies) is an innovative approach to epicutaneous immunotherapy (EPIT).
Christophe Dupont, A. Burks, David M. Fleischer, K. Bee, Sarita Chainani, Hugh A. Sampson   +5 more
semanticscholar   +1 more source

Long-Term, Open-Label Extension Study of the Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Children: PEOPLE 3-Year Results.

Journal of Allergy and Clinical Immunology, 2020
BACKGROUND We previously reported the safety and efficacy of epicutaneous immunotherapy (EPIT™) for peanut allergy (250 μg, daily epicutaneous peanut protein; DBV712 250μg) in a 12-month randomized controlled study (PEPITES) of peanut-allergic children ...
D. Fleischer, W. Shreffler, Dianne E. Campbell, Dianne E. Campbell, Todd D. Green, Todd D. Green, S. Anvari, S. Anvari, A. Assa'ad, P. Bégin, K. Beyer, J. Bird, T. Brown-whitehorn, T. Brown-whitehorn, A. Byrne, E. Chan, A. Cheema, S. Chinthrajah, H. Chong, C. Davis, Lara S. Ford, Lara S. Ford, R. Gagnon, M. Greenhawt, J. Hourihane, J. Hourihane, S. Jones, Edwin H. Kim, L. Lange, B. Lanser, Stephanie A. Leonard, Stephanie A. Leonard, V. Mahler, A. Maronna, A. Nowak‐Wegrzyn, R. Oriel, M. O'Sullivan, D. Petroni, J. Pongracic, S. L. Prescott, S. L. Prescott, L. Schneider, Peter Smith, D. Staab, G. Sussman, R. Wood, William H. Yang, R. Lambert, A. Peillon, T. Bois, Hugh A. Sampson, Hugh A. Sampson   +51 more
semanticscholar   +1 more source

Comparisons of Celiac Disease and Non-Celiac Gluten Sensitivity [PDF]

, 2020
Celiac disease (CD) and non-celiac gluten sensitivity (NCGS) are often confused or grouped together due to their commonalities. However, this is careless behavior because there are clinically significant differences between the two diseases. Similarities
Thomas, Victoria
core   +1 more source